NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Extraordinary General Meeting approves the Board’s proposals to create authorized share capital and amend the bylaws
Ad hoc announcement pursuant to Art. 53 LR of the Swiss stock exchange SIX
- Authorization of the Board to issue up to 1 million new shares until September 30, 2023.
- Amendment of the bylaws allows for exclusion of subscription rights of existing shareholders under specific circumstances.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.